US · PHARMACEUTICAL PREPARATIONS · MID CAP
Puretech Health PLC PTCHF
7 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$4.8M
▲ 45.0% vs FY2023
EPS · FY24
$0.21
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
12.2%
Net margin · FY24
1108.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.8M
Revenue, FY2024 · full 7-year series below
Revenue
Net income
1108 cents of every revenue dollar became profit this year.
Per share
USD 0.21
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
12.2%
Return on equity, FY2024
ROE
Operating margin-2818.9%
Net margin1108.3%
Return on assets8.3%
Each USD of equity produced 12 cents of profit this year.
Returned to shareholders
USD 4.8M
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 4.8M
Share of profit9.0%
Consecutive raises—
USD 4.8M in buybacks — 9% of the year's profit went back to shareholders.
Growth
−13.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−34.8%
−13.2%
Net income
−33.8%
EPS, diluted
−32.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 602.6M
total assets, end of FY2024
Total assetsUSD 602.6M
EquityUSD 414.7M
CashUSD 280.6M
Current ratio9.33×
Equity funds 69% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
EBITDA $B
−0.1
−0.1
−0.2
−0.1
·
·
·
Income tax $B
−0.0
0.0
−0.1
0.0
0.0
0.1
0.0
Net income $B
0.1
−0.1
−0.1
−0.1
0.0
0.4
−0.0
EPS, diluted $
0.21
−0.24
−0.18
−0.21
0.02
1.44
−0.16
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
12.2
−13.1
−8.9
−9.6
0.9
63.0
·
Shares out B
·
0.27
0.28
0.29
0.29
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
16 of 16
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed